1415915-01-3

Upstream product

• 289-82-7 2H-1,2-oxazine 
• 1415915-00-2 (S)-3-amino-2,2,4-trifluoro-3-(2-fluoro-phenyl)-butan-1-ol 
• 1415914-98-5 (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-2,2,4-trifluoro-3-(2-fluorophenyl)butanoate 
• 218771-68-7 1-(2-fluorophenyl)-2-hydroxyethan-1-one 
• 1402412-84-3 2-fluoro-1-(2-fluorophenyl)ethan-1-one 
• 1415914-97-4 (R)-2-methyl-propane-2-sulfinic acid [2-fluoro-1-(2-fluoro-phenyl)-eth-(E)-ylidene]-amide 

Downstream Products

• 1415915-02-4 (S)-5,5-difluoro-4-fluoromethyl-4-(2-fluoro-5-nitro-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamine 
• 1415915-03-5 (S)-4-(5-amino-2-fluoro-phenyl)-5,5-difluoro-4-fluoromethyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine 
• 1415914-91-8 (S)-N-(3-(2-amino-5,5-difluoro-4-(fluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide 

Relevant academic research and scientific papers

HALOGEN-ALKYL-1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention provides compounds of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

β-secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease

An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors. The CF3 substituted oxazine 89, a potent and

HALOGEN-ALKYL-1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention provides compounds of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present i